Rising Concerns Over Flu-Related Deaths
The latest flu season recorded more child fatalities than any year since the 2009 swine flu pandemic, with most victims unvaccinated. In an effort to boost immunization rates, particularly among children and needle-averse individuals, AstraZeneca has launched FluMist Home, the first nasal flu vaccine approved for at-home use. Available by prescription, it can be used by children aged 2 and older and adults up to 49.
From Clinic to Living Room
Originally approved in 2003 for administration in medical settings, FluMist faced reduced efficacy against H1N1 following the 2009 pandemic, leading the CDC to recommend against it in 2016. Reformulated to better match circulating strains, it returned to the market in 2018. Updated annually, the 2026-2027 formulation includes A/H1N1, A/H3N2, and B/Victoria strains. According to AstraZeneca, the nasal spray offers comparable protection to injectable vaccines, typically 40% to 60% effective at preventing severe illness.
How It Works and Who Can Use It
FluMist Home contains a weakened live virus to stimulate immunity. While safe for most healthy individuals, pregnant women and people with weakened immune systems should consult a physician before use. Administered via a nasal spray, the product mirrors the experience of using a home medical test, with guidance provided online. Concerns remain about correct self-administration, particularly in cases of nasal congestion or improper storage.
Availability, Cost, and Coverage
Exclusively sold online, FluMist Home requires customers to complete a medical screening at FluMist.com. Once approved, the pharmacy coordinates insurance billing and ships the product with a temperature monitor to ensure proper storage during transit. For insured patients, costs are generally limited to an $8.99 shipping fee. Without insurance, FluMist is currently only available in healthcare settings, though a direct-purchase option is planned for future seasons. Most insurance plans, including Medicare and Medicaid, cover the vaccine when given in a clinic.